Darbepoetin alfa biosimilar - AvesthaGen

Drug Profile

Darbepoetin alfa biosimilar - AvesthaGen

Alternative Names: Avdesp™

Latest Information Update: 01 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Avesthagen
  • Developer Avesthagen; Quintiles
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 01 Mar 2016 No recent reports on development identified - Phase-III for Anaemia in India (Parenteral)
  • 17 Jun 2011 Darbepoetin alfa biosimilar - AvesthaGen is available for global licensing as of 17 Jun 2011. http://www.avesthagen.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top